Nexigen Overview

  • Founded
  • 2007
  • Status
  • Out of Business
  • Employees
  • 11
  • Latest Deal Type
  • Out of Business

Nexigen General Information


Developer of drugs designed to provide treatment of cancer and viral infections. The company's drugs uses oncological indications and disease mechanisms to develop therapeutics for cancer by reducing the gap between small molecule drugs and therapeutic antibodies, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • Biocampus Cologne, Building S19
  • Nattermannallee 1
  • 50829 Cologne
  • Germany
+49 0221 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nexigen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Out of Business 01-May-2016 000.00 Completed Out of Business
5. Grant 01-Dec-2014 00.000 000.00 Completed Generating Revenue
4. Later Stage VC 01-Nov-2014 00.000 000.00 Completed Generating Revenue
3. Early Stage VC 01-Jun-2011 00.000 00.000 Completed Startup
2. Grant 16-Apr-2010 $1.89M Completed Generating Revenue
1. Corporate 26-May-2008 Completed Startup
To view Nexigen’s complete valuation and funding history, request access »

Nexigen Executive Team (7)

Name Title Board Seat Contact Info
Jan Jennes Controller, Finanace
Burkhard Heil Co-Founder & Head of Bio-Information Technology
Claudia Carl Ph.D Co-Founder & Head of Early Discovery
Annette Friebe Ph.D Co-Founder
You’re viewing 4 of 7 executive team members. Get the full list »

Nexigen Board Members (3)

Name Representing Role Since
Linda Hakes Ph.D Nexigen Board Member 000 0000
You’re viewing 1 of 3 board members. Get the full list »

Nexigen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial